DXCM vs RLAY · P/E 63, rev $2.50B vs rev $3.4M
DexCom Inc (DXCM) versus Relay Therapeutics Inc (RLAY) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Relay Therapeutics Inc (RLAY) is a biotechnology company listed on NASDAQ.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported RLAY revenue for 2026-06-30 was $3.4M. Net income was -$157.0M. Revenue was up 11.7% from 2026-03-31 to 2026-06-30. RLAY currently screens at market cap $3.39B.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. RLAY currently screens at market cap $3.39B.
Not investment advice. Open the DXCM and RLAY stock pages for the full models.
Not investment advice.